Results 51 to 60 of about 386,285 (319)

The TET3/GATA6 Axis Drives Lipid Metabolism and Therapeutic Vulnerabilities in Pancreatic Ductal Adenocarcinoma

open access: yesAdvanced Science, EarlyView.
The DNA demethylase TET3 drives lipid metabolic reprogramming in pancreatic ductal adenocarcinoma via a non‐catalytic mechanism. TET3 recruits histone deacetylases to repress GATA6, sustaining lipogenic enzyme expression and ferroptosis resistance.
Shuai Liu   +8 more
wiley   +1 more source

Mature Nasopharyngeal Teratoma in a Child

open access: yesCase Reports in Otolaryngology, 2015
Teratomas are neoplasms derived from the germ cell with components of all the three embryonic layers. These are rare neoplasms in head and neck region which can occur in any age group but are more prevalent in children. The present case is an 11-year-old
Ramesh Parajuli   +2 more
doaj   +1 more source

Diffusion-weighted Magnetic Resonance Imaging Evaluates Salivary Gland Function Damage in Nasopharyngeal Carcinoma Patients Treated with Intensity-modulated Radiation Therapy

open access: yesZhongliu Fangzhi Yanjiu, 2019
Objective To evaluate salivary gland function damage and analyze related factors by diffusion-weighted magnetic resonance imaging (DW-MRI) in patients with nasopharyngeal carcinoma after intensity modulated radiation therapy.
LIU Guichao   +6 more
doaj   +1 more source

Extra-Nasopharyngeal Angiofibroma of the Hard Palate: An Uncommon Case Reported in an Adult Female

open access: yesIndian Journal of Dental Education
Angiofibromas, accounting for a mere 0.05-0.5% of all head and neck neoplasms, are uncommon benign tumors originating from connective tissue and characterized by a high vascularity and local aggressiveness.
Ishita Singhal   +3 more
semanticscholar   +1 more source

Potentially functional variants of autophagy‐related genes are associated with the efficacy and toxicity of radiotherapy in patients with nasopharyngeal carcinoma

open access: yesMolecular Genetics & Genomic Medicine, 2019
Nasopharyngeal carcinoma (NPC) is one of the major invasive malignant neoplasms of head and neck, while radiotherapy is the primary therapy for NPC. Genetic variants could affect the efficacy and toxicities of radiotherapy in NPC patients.
Zhiguang Yang, Zhaoyu Liu
semanticscholar   +1 more source

A Prion‐Like Domain in EBV EBNA1 Promotes Phase Separation and Enables SRRM1 Splicing

open access: yesAdvanced Science, EarlyView.
This study discoveries that EBV EBNA1 behaves as a prion‐like protein, verified using cell‐based assays and the Saccharomyces cerevisiae Sup35p prion identification system. The prion‐like domain of EBNA1 drives liquid–liquid phase separation. EBNA1 interacts with the splicing factor SRSF1 to regulate the expression of the SRRM1 splicing isoforms ...
Xiaoyue Zhang   +17 more
wiley   +1 more source

Radiation Exposure Induced Blood–Brain Barrier Injury via Mitochondria‐Mediated Sterile Inflammation

open access: yesAdvanced Science, EarlyView.
This work describes a blood–brain barrier (BBB) microphysiological system (MPS) to explore the responses of BBB to radiation exposure. Following radiation exposure, obvious BBB comprise and brain endothelial injuries are detected. Mechanism study shows radiation induced significant sterile inflammation via mitochondrial dysfunction and cGAS‐STING ...
Peng Wang   +6 more
wiley   +1 more source

Clonal heterogeneity of polymorphic B-cell lymphoproliferative disease, EBV-positive, iatrogenic/immune senescence: implications on pathogenesis and treatment

open access: yesHematology, 2022
Background Epstein Barr virus positive (EBV+) immunodeficiency-associated lymphoproliferative disorders (IA-LPD) are heterogeneous diseases with variable treatment strategies that are not well-defined.Case presentation A 68-year-old woman with systemic ...
Yu-Yan Hwang   +4 more
doaj   +1 more source

Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China

open access: yesFrontiers in Immunology, 2022
Toripalimab (Tuoyi™) is a selective, recombinant, humanized monoclonal antibody against programmed death protein 1 (PD-1) developed by Shanghai Junshi Bioscience Co., Ltd.
Lin Zhang   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy